HK Stock Market Move | TENNOR THERAP-B (06872) rose over 7% intraday; TNP-2092 prioritizes development of intra-articular injection for the treatment of prosthetic joint infection indications.

TENNOR THERAP-B (06872) rose over 7% intraday. As of press time, it was up 7.66% at HK$70.7, with a turnover of HK$6.3225 million. On the news front, on October 30, TENNOR THERAP-B issued an announcement stating that, after comprehensively considering the existing clinical data, unmet clinical needs, competitive landscape, and commercial potential of the investigational new drug candidate rifaquinozone (TNP-2092), the company has selected intra-articular injection for the treatment of prosthetic joint infection (PJI) as the core priority development indication for rifaquinozone. As the Group's core pipeline, rifaquinozone has application prospects across multiple indications. The Phase IIa proof-of-concept clinical trial of rifaquinozone administered via intra-articular injection for the treatment of PJI as an alternative to surgery achieved positive results, and the first patient has been enrolled in the multicenter Phase IIb clinical trial. The trial is designed to further evaluate the efficacy, safety, and pharmacokinetic characteristics of rifaquinozone in treating PJI without debridement or revision surgery, marking a critical stage in the clinical development of this potentially disruptive new drug product.